Drug-Drug Interaction Study of ABP-671 in Gout Patients

Open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

Inclusion Criteria:

• Adults 18-75 years with clinical diagnosis of gout.
• Stable Allopurinol therapy QD for ≥14 days prior to Day 1.
• Cohort N: Normal renal function.
• Cohort R: Moderate renal impairment.

Exclusion Criteria:

• Clinically significant hepatic impairment.
• History of Allopurinol hypersensitivity.
• Pregnancy or breastfeeding.